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Mesenchymal progenitor cell characteristics that can identify progenitor populations with specific functions in immunity are
actively being investigated. Progenitors from bone marrow and adipose tissue regulate the macrophage (MΦ) inflammatory
response by promoting the switch froman inflammatory to an anti-inflammatory phenotype. Conversely,mesenchymal progenitors
from the mouse aorta (mAo) support and contribute to the MΦ response under inflammatory conditions. We used cell lines with
purported opposing immune-regulatory function, a bonemarrow derivedmesenchymal progenitor cell line (D1) and amouse aorta
derived mesenchymal progenitor cell line (mAo). Their interaction and regulation of the MΦ cell response to the inflammatory
mediator, lipopolysaccharide (LPS), was examined by coculture. As expected, D1 cells suppressed NO, TNF-𝛼, and IL-12p70
production but MΦ phagocytic activity remained unchanged. The mAo cells enhanced NO and TNF-𝛼 production in coculture
and enhanced MΦ phagocytic activity. Using flow cytometry and PCR array, we then sought to identify sets of MSC-associated
genes andmarkers that are expressed by these progenitor populations.We have determined that immune-supportive mesenchymal
progenitors highly express chondrogenic and tenogenic transcription factors while immunosuppressive mesenchymal progenitors
highly express adipogenic and osteogenic transcription factors. These data will be useful for the isolation, purification, and
modification of mesenchymal progenitors to be used in the treatment of inflammatory diseases.
1. Introduction
Multipotent stromal cells also known as mesenchymal stem
cells (MSC) are nonhematopoietic stem/progenitor cells
originally isolated from the bone marrow that give rise to
connective tissues in the embryo and are present in adult
mammalian tissues [1]. MSC are active in the repair of tissues
by replacing damaged cells but more recently they have been
studied for their immunoregulatory properties [1, 2]. Due to
their capacity to suppress and regulate inflammation through
direct and indirect contact with T-cells andmacrophage cells,
MSC are ideal candidates for use in cell-based therapies
of inflammatory diseases. Phase II and phase III clinical
trials investigating the therapeutic use of MSC in treat-
ing graft-versus-host disease, Crohn’s disease, progressive
multiple sclerosis, kidney transplant rejection, and ischemic
cardiomyopathy are in progress [3].
MSC suppress T-cell responses by reducing their pro-
liferation [4, 5], inducing apoptosis [6], and support-
ing the differentiation of the regulatory T-cell phenotype
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[7]. MSC regulation of macrophage cells (MΦ) has not
been as extensively studied and current studies have dis-
parate results. MSC derived from bone marrow, adipose,
and placental tissues promote the differentiation of the
anti-inflammatory macrophage phenotype [8–10]. On the
other hand, macrophage-associated MSC can also dis-
play an inflammatory phenotype [11] and recent work has
revealed that mesenchymal progenitor cells from the mouse
aorta (mAo) contribute to and support the inflammatory
macrophage [12]. The MSC phenotypic characteristics that
underlie their anti-inflammatory properties are under active
investigation and many recent studies explore the relation-
ship between heterogeneity in surface antigen expression and
heterogeneity in functional properties among MSC [13].
In this study, we compared the ability of the mAo mes-
enchymal progenitor and a bone marrow derived mesenchy-
mal progenitor cell line (D1) to regulate the inflammatory
response of MΦ. mAo and D1 cells were cocultured with
bonemarrow derivedMΦ and exposed to lipopolysaccharide
(LPS). Nitric oxide (NO), tumor-necrosis factor-𝛼 (TNF-𝛼),
and interleukin-12 (IL-12) were used as markers of inflamma-
tion. Additionally, we examined the effect of coculture on the
phagocytic index of MΦ in response to zymosan exposure.
Then, to correlate their immune-regulatory capacity to their
phenotypic profile, we measured the MSC surface antigens
CD44, CD73, Sca-1, CD105, and CD106 using flow cytometry
and measured expression of MSC-associated genes using a
PrimePCR mesenchymal stem cells PCR gene array.
2. Materials and Methods
2.1. Materials. All cell culture media, trypsin, FBS, and
antibiotic/antimycotic solutions were obtained from Invitro-
gen (Carlsbad, CA). The L-929 fibroblast (CCl-1) was pur-
chased from theAmericanTypeTissueCollection (Manassas,
VA). The FITC rat anti-mouse CD44 (Cat. #553133), PE rat
anti-mouse CD 105 (Cat. # 562759), PE rat anti-mouse Ly-
6AE (Sca-1) (Cat. # 561076), FITC rat anti-mouse CD45 (Cat.
#553080), FITC rat anti-mouse CD106 (Cat. #553332), PE rat
anti-mouse CD73 (Cat. #557041), and FITC rat anti-mouse
CD11b (Cat. #553310) were purchased from BD Biosciences.
Gamma irradiated LPS from E. coli (#L4391) and all other
chemicals and reagents were purchased from Sigma-Aldrich
(USA) unless otherwise specified.
2.2. Animals. All animal protocols were approved by the
Winthrop University Hospital’s Animal Care and Use Com-
mittee and adhere to the regulations outlined by the National
Institutes of Health. C57BL/6 male mice were obtained from
Taconic, North America. Animals were housed under local
vivarium conditions (12 h light-dark cycle) and allowed to
acclimate for at least 7 days prior to experimentation. Mice
were euthanized under CO
2
at 8–12 weeks of age and aorta
and hind limbswere removed in preparation for cell isolation.
2.3. Cell Culture
2.3.1. AorticMesenchymal Progenitor Cell Line (mAo). Mouse
aortic progenitor lines were derived from C57BL/6 mice
using the method of da Silva Mierelles [14] with slight
modification as described in [15].
2.3.2. Bone Marrow Derived Mesenchymal Progenitor Cells.
(D1) D1 ORLUVA (D1) cells, a bone marrow-derived mesen-
chymal stem cell line, were obtained from the American Type
Culture Collection (ATCC #CRL-12424) and maintained in
DMEM supplemented with 10% FBS, 100U/mL penicillin
sodium, 100U/mL streptomycin sulfate, and 0.25𝜇g/mL
amphotericin B.
2.3.3. Bone Marrow-Derived Macrophage Cells (MΦ). Bone
marrow from the hind limbs of the C57BL/6 mouse was
isolated as previously described [16]. After creating a single-
cell suspension, nucleated cells were counted using 3% acetic
acid/trypan blue exclusion and plated in DMEM supple-
mented with 10% fetal bovine serum (FBS), 15% L929 fibrob-
last cell conditioned medium, 100U/mL penicillin sodium,
100U/mL streptomycin sulfate, and 0.25 𝜇g/mL ampho-
tericin B at 107 cells per 100mm Petri dish. The L929 condi-
tioned medium was prepared as suggested by the ATCC.The
L-929 cell line produces M-CSF which supports the growth
and differentiation of macrophages from the bone marrow.
After 3 days, half themediumwas removed and replaced with
fresh medium. A complete medium change was performed
on day 6. At day 7 of culture monocyte/macrophage cells
were replated according to experimental objectives, passed
or frozen, and stored in liquid nitrogen (LN
2
). Cultures up
to passage 2 were used in experiments.
2.3.4. Coculture. The mAo cells were initiated at a density
of 1.5 × 104/cm2 and the D1 were initiated at a density of
3.25 × 103/cm2. The cells were initiated at different densities
because when plated at the same density, the D1 cells will
reach confluence earlier. In order to carry out the cocul-
ture experiments with both cell populations with the same
timeline, it was necessary to initiate the D1 cells at a lower
density. They have similar cell numbers at confluence. When
the mesenchymal progenitor cultures reached confluence,
MΦ were added at a density of 1.0 × 105/cm2 and allowed
to attach overnight. Cultures were then washed with serum-
free DMEM supplemented with 0.02% BSA and then left
untreated or were treated with LPS (100 ng/ml) for 24 h in
fresh serum-free DMEM/0.02% BSA. Culture supernatants
were then collected and stored at −80∘C until assay.
2.4. Flow Cytometry. For staining of mAo MSC and D1 MSC
surface markers, single-cell suspensions were first incubated
with Fc receptor blocking reagent (Miltenyi Biotec) followed
by staining with antibodies against surface markers CD29,
CD44, CD73, CD105, CD106, Sca-1 (Ly-6AE), and CD45 for
30min at 4∘C. After incubation, cells were washed twice in
wash buffer (1% FBS in PBS) and analyzed with an Accuri C6
flow cytometer.
2.5. Nitrite Measurements. Nitrite, as a reflection of nitric
oxide (NO) production, was measured in cell culture super-
natant using the Griess Reagent system (Promega, Madison,
WI) according to the manufacturer’s instructions.
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2.6. Secreted Cytokine and Chemokine Measurements. TNF-
𝛼 and IL-12p70 cytokines were measured in culture super-
natants using Ready-SET-Go! ELISA kits from eBioscience
(San Diego, CA).
2.7. Phagocytosis Assay. MΦ and cocultures of MΦ/mAo and
MΦ/D1 were initiated in 4-well chamber slides and incubated
overnight. Zymosan-A S. cerevisiae BioParticles, fluorescein
conjugate (Molecular Probes), was added at 5 and 10 particles
per MΦ cell and incubated for 45 minutes. The chambers
were then rinsed gently 4x with cold PBS and fixed in 4%
paraformaldehyde (PFA) followed by mounting in hard-set
DAPI mounting medium (Vector Laboratories) to stain the
nuclei. Ten to twelve fluorescent digital micrographs were
taken of each culture type and analyzed for intracellular
zymosan-A. Phagocytic cells were categorized into groups
according to the number of ingested particles and data is
presented as [1–5], [6–10], [11–15], and [16+] particles per cell.
2.8. Gene Expression
2.8.1. Gene Array. A PrimePCR mesenchymal stem cells
(SAB target list) PCR gene array from Bio-Rad was used
to compare the MSC gene-expression profiles of the mAo
and D1 cultures. RNA was extracted from the cultures using
TRIzol reagent (Invitrogen) according to the manufacturer’s
instructions. After quantization, 2𝜇g total RNA was reversed
transcribed using the iScript Advanced cDNA Synthesis kit
(Bio-Rad). The reaction mix was prepared as directed using
Sso Advanced Universal SYBR Green supermix (Bio-Rad) to
yield 20 ng cDNA per reaction in the PCR array.
2.8.2. Real-Time Reverse Transcription PCR. Real-time rev-
erse transcription PCR was carried out using Sso Advanced
Universal SYBR Green supermix and the CFX96 Touch
Real-Time PCR System from Bio-Rad. Primer sequences
were specific for mouse: Pparg forward 5󸀠-CGGGCTGAG-
AAGTCACGTT-3󸀠 Pparg reverse 5󸀠–TGTGTCAACCAT-
GGTAATTTCAGT-3󸀠, Sox2 forward 5󸀠–GATCAGCAT-
GTACCTCCCCG-3󸀠 Sox2 reverse 5󸀠–TCCTCTTTTTGC-
ACCCCTCC-3󸀠, Sox9 forward 5󸀠-GGGCGAGCACTCTGG-
GCAAT-3󸀠 Sox9 reverse 5󸀠-CGTCGCGGAAGTCGATGG-
GG-3󸀠, and Runx2 forward 5󸀠- CCCTGAACTCTGCAC-
CAAGT-3󸀠 Runx2 reverse 5󸀠-TGGAGTGGATGGATGGGG-
AT-3󸀠. PCR conditions were 95∘C for 5min followed by 40
cycles of 95∘C 10 s, 55∘C, 10 s, and 72∘C for 30 s.
2.9. Statistical Analyses. Unless otherwise indicated, data
were analyzed using one-way ANOVA. Bonferroni’s posttest
was used to determine statistical differences between groups.
3. Results
3.1. When in Coculture with MΦ, mAo MSC Enhance While
D1 MSC Suppress LPS-Induced Inflammation. Nitric oxide
(NO) is a hallmark of inflammation and is produced by
MΦ in an acute response to inflammatory stimuli [17] but
can also be produced by MSC to regulate T-cells [2, 18].
Previous studies have indicated that mAo progenitors pro-
duce NO synergistically in coculture withMΦ [12]. Although
many previous studies have determined that bone marrow
derived progenitors suppress MΦ secretion of inflammatory
cytokines, there is a paucity of studies that have examined
the production of NO in cocultures of bone marrow derived
progenitors and MΦ. Here we compared the production
of NO in D1/MΦ with that of mAo/MΦ cocultures after
exposure to LPS.
As previously determined [12], the mAo/MΦ culture
produced NO at synergistic levels significantly above MΦ
or mAo cells cultured alone (∼28𝜇M in mAo MSC/MΦ
versus ∼11 𝜇M in MΦ and ∼5 𝜇M in mAo MSC, 𝑃 < 0.001)
(Figure 1(a)). In T-cell studies, NO produced by MSC results
in immunosuppression of T-cells in close proximity [19]. MΦ
also use NO to mediate their cytotoxic effects but are also
susceptible to apoptosis upon exposure to NO. Whether in
the case of mAo/MΦ interaction enhanced NO production
leads to MΦ apoptosis and the subsequent suppression
of the innate immune response and/or contributes to the
suppression of T-cell responses remains to be determined.
In contrast, the D1/MΦ coculture produced significantly less
NOwhen compared toMΦ cultures (∼5𝜇MinD1/MΦ versus
∼11 𝜇M in MΦ, 𝑃 < 0.05) (Figure 1(a)). The significant
decrease in NO production in the D1/MΦ cultures is in
line with previous studies demonstrating that bone marrow
mesenchymal progenitors promote the switch of the MΦ
from the inflammatory to anti-inflammatory phenotype [8,
9].
IL-12p70 and TNF-𝛼 are not expressed by mesenchymal
progenitors [12, 20, 21] and therefore these cytokines were
used to examine the inflammatory profile of MΦ while in
coculture with mAo and D1 progenitor cells. Cytokine secre-
tion of the cocultured cells was compared to that of the MΦ
cells cultured alone. Coculture with mAo increased TNF-
𝛼 secretion by MΦ (∼26 ng/mL in MΦ versus ∼32 ng/mL
in mAo MSC/MΦ, 𝑃 < 0.001) and in D1/MΦ cocultures
it was significantly reduced (∼18 ng/mL in D1/MΦ versus
∼26 ng/mL in MΦ, 𝑃 < 0.001) (Figure 1(b)). IL-12p70
secretion in mAo/MΦ cultures did not significantly deviate
from MΦ cultures (∼2.8 ng/mL versus ∼3.2 ng/mL, resp.)
(Figure 1(c)). On the other hand, in D1/MΦ cultures, IL-
12 secretion was significantly reduced (∼3.2 ng/mL in MΦ
versus ∼0.4 ng/ml in D1/MΦ, 𝑃 < 0.001) (Figure 1(c)). These
data establish that the D1 bone marrow derived progenitors
suppress while those from the aorta (mAo) contribute to the
inflammatory profile of MΦ activated by LPS consistent with
previous works [10, 22].
3.2. The Phagocytic Index of MΦ Is Increased in Response
to Zymosan When in Coculture with mAo. In addition to
establishing the impact of MΦ and mesenchymal progenitor
cell-cell interaction on the inflammatory milieu, we also
examined the impact on MΦ phagocytic activity. MSC are
known to induce an increase in MΦ phagocytosis consistent
with their promotion of the anti-inflammatory phenotype
[23]; however, the influence the mAo and D1 cells have
on MΦ phagocytosis has not been previously determined.
Zymosan-A particles were added to cocultures of D1/MΦ
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Figure 1: When in coculture with MΦ, aortic mesenchymal progenitor cells, mAo, enhance while bone marrow-derived mesenchymal
progenitor cells, D1, suppress LPS-induced NO, TNF-𝛼, and IL-12p70 production. Nitrite production as a measure of NO (a), TNF-𝛼 (b), and
IL-12p70 (c) was measured in culture supernatants of mAo MSC, D1 MSC, and MΦ cultured alone and in coculture. Cultures were treated
with LPS (100 ng/mL) for 17 hr. Data are presented as mean ± SEM and are representative of 3 experiments each with 𝑛 = 4. ∗Significantly
different fromMΦ alone, 𝑃 < 0.05, ∗∗∗significantly different fromMΦ alone, 𝑃 < 0.0001.
and mAo/MΦ at a density of 5 and 10 particles per MΦ cell,
levels below saturation as determined in preliminary studies.
Ingested, cell-associated zymosan-A particles were counted
and results were presented as ranges representing different
levels of activity. The ranges of increasing activity include
[1–5], [6–10], [11–15], and [16+] particles ingested per cell
(Figures 2(a) and 2(b)). A shift to the right in the bar graph
(from the low to high ranges) correlates with an increase in
phagocytic activity.
Coculture with D1 had no effect on MΦ phagocytosis
of zymosan-A particles at 5 or 10 particles per cell; note
the similar pattern in bar graphs of D1/MΦ and MΦ in
Figure 2(b). Additionally, when MΦ were in coculture with
the mAo, the phagocytic activity of the MΦ was enhanced,
reflected in a shift of the mAo/MΦ bar graph to the right
when compared to MΦ in Figure 2(b). Taken together, data
from the cytokine and phagocytosis assays indicate that D1
progenitors suppress LPS-induced inflammatory pathways
but have no effect on those induced by zymosan. The
mAo progenitors however support both LPS-induced and
zymosan-induced MΦ activity.
3.3. Correlation of mAo and D1 Phenotypic Profiles with
Their Immune-Regulatory Functions. Afterwe established the
immune-regulatory functions of mAo and D1 cells when
in coculture with MΦ under inflammatory conditions, we
then sought to determine their phenotypic and genotypic
profiles. Our goal was to relate their functional properties to
their expression of mesenchymal progenitor cell-associated
markers.
3.3.1. MSC-Associated Antigen Expression. As expected, both
cell populations are negative for the hematopoietic markers,
CD45 and CD11b. Both cell types were also positive for
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Figure 2: The phagocytic index of MΦ is increased when in coculture with aortic mesenchymal progenitor cells, mAo. Fluorescent
micrographs of MΦ, mAo/MΦ, and D1/MΦ cultures exposed to 5 and 10 particles of FITC labeled zymosan-A per MΦ cell. Cultures were
counterstained with DAPI to delineate nuclei (a). Micrographs were used to quantify MΦ uptake of zymosan particles. Counts per cell are
presented in the following ranges: [1–5], [6–10], [11–15], and [16+] zymosan-Aparticles per cell (b).Data represent findings from3 experiments,
each with an 𝑛 = 4.
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Figure 3: Flow cytometry ofMSC-associated antigens in aorticmesenchymal progenitor cells, mAo, and bonemarrow-derivedmesenchymal
progenitor cells, D1. Flow cytometry was performed to detect CD45, CD11b, CD44, CD73, Sca-1, CD105, and CD106 surface antigens in mAo
(a) and D1 (b) cultures.
the MSC-associated antigens, CD29, CD44, and Sca-1, but
differed in their expression of CD73, CD105, and CD106.The
D1 cell cultures are heterogeneous for the expression of the
CD73 marker but negative for CD105 and CD106. On the
other hand, mAo cells are negative for CD73 and positive for
CD105 andCD106 (Figures 3(a) and 3(b)). Results of theMSC
gene specific reverse transcription PCR array confirmed the
differences in expression of CD73, CD105, and CD106 and
also uncovered differential expression of CD90 (Table 1).
In 2006, theMesenchymal andTissue StemCell Commit-
tee of the International Society forCellularTherapy published
a position paper outlining minimum criteria for the MSC
designation in human cell populations.Theminimumcriteria
are that MSC must be capable of multipotent differentiation,
be negative for leukocyte specific antigens, and at aminimum
express the cell surface markers, CD73, CD90, and CD105
[24]. Formouse cells, however, no clear criteria have emerged
and there are many differences in MSC surface antigen
expression betweenmouse and human cells [25].There is also
a great variation in reported MSC surface antigen expression
and many new potential identifying antigens are continually
emerging [26]. Both the D1 and mAo cells used in these
studies are capable of multipotent differentiation [22] but
have differing surface antigen profiles and therefore we use
the term mesenchymal progenitor.
Expression of CD73 on the D1 cells is in line with
their downregulation of the inflammatory environment in
the cocultures. CD73 is a 5󸀠 ectonucleotidase, an enzyme
Stem Cells International 7
Table 1: Genes differentially expressed in mAo and D1 progenitor stem cells.
Gene symbol ΔCqmAo/D1 Specific function
MSC-associated surface antigens
Endoglin (CD105) Eng (+/−)
Coreceptor for TGF𝛽1 and TGF-𝛽3 [29].
Expression on mouse MSC is heterogeneous
and expression reduces adipogenic and
osteogenic differentiation capacity and
increases capacity for inhibition of T-cell
proliferation [13].
5󸀠-nucleotidase, ecto (CD73) Nt5e (−/+)
Generates extracellular adenosine by
dephosphorylation of adenosine
5󸀠-monophosphate and plays a role in MSC
osteogenic differentiation [30].
Thymus cell antigen 1, theta (CD90) Thy1 (+/−)
Originally discovered as a thymocyte
antigen. Blocks adipogenesis and PPAR𝛾
[31].
Transcription factors
K(lysine) acetyltransferase 2B Kat2b 4.27
Also known as P300/CBP-associated factor
(PCAF). A chromatin histone
acetyltranferase involved in transactivation
of chondrogenic genes [25].
Peroxisome proliferator activated receptor gamma Pparg −8.12 Nuclear receptor and established majorinducer of adipogenesis [32].
Runt related transcription factor 2 Runx2 −7.26
Also known as Cbfa1. A bone transcription
factor involved in the osteogenic
differentiation of MSC [33].
SRY-box containing gene 2 Sox2 (−/+)
An embryonic transcription factor that
regulates lineage differentiation and
proliferation of human MSC [34].
SRY-box containing gene 9 Sox9 3.17
A major chondrogenic transcription factor
that is also involved in regulation of
proliferation and adipogenic and osteogenic
differentiation of MSC [35].
Growth factors
Brain derived neurotrophic factor Bdnf 4.93
Stimulates nerve cell differentiation and
maturation; MSC secreted BDNF protects
nerve cells from apoptosis and enhances
endogenous neurogenesis [36].
Bone gamma carboxyglutamate protein Bglap (−/+)
Highly conserved protein associated with
mineralized bone matrix [37]. Also known
as osteocalcin; used as a marker of MSC
osteogenic differentiation [38].
Bone morphogenetic protein 2 Bmp2 (−/+) Facilitates the osteogenic differentiation ofMSC [39].
Fibroblast growth factor 2 Fgf2 (+/−)
Promotes proliferation [40] and
downregulates senescence in BMMSC
cultures [41].
Growth differentiation factor 7 Gdf7 (+/−) Promotes tenogenic differentitation ofmesenchymal stem cells [42].
Hepatocyte growth factor Hgf (+/−)
HGF and its primary receptor cMET play a
critical role in MSC stimulated recovery in
experimental autoimmune
encephalomyelitis [43].
Insulin-like growth factor 1 Igf1 (+/−)
Treatment of MSC with IGF-I increases
their engraftment in a rat model of
myocardial infarction [44].
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Table 1: Continued.
Gene symbol ΔCqmAo/D1 Specific function
Platelet derived growth factor receptor, beta polypeptide Pdgfrb 7.21
A cell surface tyrosine kinase receptor for
members of the platelet-derived growth
factor (PDGF) family. Blocks adipogenic
differentiation by blocking PPARy and
CEPB𝛼 expression; promotes MSC
self-renewal [45].
Transforming growth factor beta-3 Tgfb3 3.52 Promotes and improves chondrogenesis inMSC populations [46].
Matrix/cell adhesion/cytoskeleton
Collagen, type I, alpha 1 Col1a1 3.03 An extracellular matrix protein thatpromotes MSC proliferation [47].
Integrin alpha 6 Itga6 −3.25
Also known as CD49f. A cell adhesion
molecule that enhances multipotency
through direct regulation of OCT4 and
SOX2 in human MSC [48].
Melanoma cell adhesion molecule (CD146) Mcam (+/−)
Cell adhesion molecule participating in
heterotypic intercellular adhesion [49]. Its
expression reflects the perivascular origin of
the MSC [50].
Matrix metallopeptidase 2 Mmp2 (+/−)
An enzyme that cleaves Type IV collagen of
endothelial basement membranes and
enhances the migration potential of MSC
through the endothelium [51].
Nestin Nes (+/−)
An intermediate filament neural stem cell
marker whose expression is downregulated
during neuronal or glial cell development.
Nes+ MSC are quiescent in bone marrow
and have high CFU-f activity and trilineage
differentiation [52].
Vascular cell adhesion molecule 1 (CD106) Vcam1 (+/−)
Mediates the attachment of hematopoietic
cells [53]. Serves as a marker for MSC with
T-cell immunosuppressive activity [54].
Vimentin Vim 5.05 A major intermediate filament of MSC thatplays a positive role in MSC migration [55].
Immune-related/miscellaneous
Frizzled homolog 9 (Drosophila) Fzd9 (−/+)
A receptor for Wnt-2; functions in
Wnt/𝛽-catenin signaling [56] that can
regulate phase-specific functionality of
MSCs [57]. Upregulated in early stages of
osteogenic differentiation [58].
Jagged 1 Jag1 22.11
Cell-surface antigen of Notch1; required for
regulatory T-cell expansion induced by MSC
[59].
Interleukin-6 Il-6 (+/−)
Plays a role in inhibition of lymphocyte
apoptosis by MSC [60]. MSC inhibit
dendritic cell differentiation through IL-6
[61].
Leukemia inhibitory factor Lif (+/−)
Upregulates pluripotency markers in
adipose-tissue derived mesenchymal stem
cells [62].
Notch gene homolog 1 (Drosophila) Notch1 (+/−)
Cell surface receptor for Jagged 1; required
for Treg-cell expansion induced by MSC
[59].
Stem Cells International 9
that in tandem with CD39 is responsible for catalyzing the
second step in the generation of adenosine from the adeno-
sine triphosphate released from cells into the extracellular
fluid. Adenosine then acts on adenosine receptors expressed
on leukocytes and generally suppresses their inflammatory
response [27]. CD73 expressed on MSC contributes to
immunosuppression of T-cell activity during autoimmune
responses [28]. However, because the D1 cell cultures are
heterogeneous for CD73, direct evidence of CD73 in D1
mesenchymal progenitor regulation of MΦ is warranted.
Moreover, due to their location, surface antigens are very
likely involved in cell-cell regulatory interaction between the
mesenchymal progenitors and MΦ. Therefore, the potential
roles of CD105 and CD106 in the regulatory function of the
mAo progenitors should also be a focus of future investiga-
tions.
3.3.2. PCR Array Analyses. The PCR array used in our
studies encompasses 92 genes associated with mesenchymal
stem cells, including the surface marker genes discussed
above. When focusing on the results of the array, we used
30 cycles as a stringent threshold Cq value to determine
expression. We then categorized the expression differences
as (1) differentially expressed, (2) equivalently expressed,
or (3) expressed in neither cell population. Only genes
with ≥3-fold expression difference were considered to be
differentially regulated. The raw gene array data can be
found in Supplemental File 1 (in Supplementary Mate-
rial available online at https://doi.org/10.1155/2017/5846257).
Genes that were equivalently expressed or not expressed
in the two cell populations were discounted as being
the reason for their opposing immune-regulatory func-
tions. We then classified the differentially expressed genes
according to function or utility. The classifications used
were MSC-associated surface antigens, transcription factors,
growth factors, matrix/cell adhesion/cytoskeletal elements,
and immune-related/miscellaneous (Table 1).
3.3.3. MSC-Associated Gene-Expression Patterns
Transcription Factors. Patterns of transcription factor genes
demonstrate that SRY-box containing gene 2 (Sox2) is
expressed in D1 but not in mAo progenitors. Peroxisome
proliferator activated receptor 𝛾 (Ppar𝛾) and runt related
transcription factor 2 (Runx2) also exhibit a greater expres-
sion inD1 than inmAoby 8.12- and 7.26-fold, respectively. On
the other hand, growth differentiation factor 7 (Gdf7/Bmp12),
K(lysine) acetyltransferase 2B (Kat2B/PCAF), and SRY-box
containing gene 9 (Sox9) are more highly expressed in mAo
cells compared to D1 (Figure 4 and Table 1). Using real-
time reverse transcription PCR, we were able to confirm
the differential regulation of Sox2, Ppar𝛾, Runx2, and Sox9
among D1 and mAo mesenchymal progenitor populations
(Figure 4(b)).
Ppar𝛾 is a key regulator of adipocyte differentiation and
glucose homeostasis [32]. Runx2 protein is essential for
osteoblast differentiation and skeletal morphogenesis and
acts as a scaffold for nucleic acids and regulatory factors
involved in skeletal gene expression [33]. Sox2 is essential
for self-renewal and proliferation of osteoblast precursors
[34]. The fact that these transcription factors are all highly
expressed in D1 cells indicates that they are poised for adi-
pogenic and/or osteogenic differentiation. Gdf7 is a key reg-
ulator of tenogenic differentiation of mesenchymal stem cells
[42]. Sox9 is essential formesenchymal condensation prior to
chondrogenesis and for inhibiting chondrogenic hypertrophy
while Kat2B/PCAF is a chromatin histone acetyltransferase
involved in transactivation of chondrogenic genes [25].
Upregulated expression in Gdf7, Kat2B/PCAF, and Sox9
suggests that mAo are primed for chondrogenic/tenogenic
differentiation.
Growth Factors. The patterns of differentially expressed
growth factor genes among D1 and mAo progenitor pop-
ulations are in line with patterns of transcription factor
expression (Figure 4(a) and Table 1). Bone gamma carboxyg-
lutamate protein (Bglap) and bone morphogenetic protein 2
(Bmp2) are expressed in D1 cells and not in mAo cells. Bmp2
is an osteogenic marker and its expression induces osteoblast
differentiation [39] while Bglap is a highly conserved protein
that participates in ossification and is associated with a
mineralized bone matrix [37, 38]. Platelet derived growth
factor receptor, beta polypeptide (Pdgfrb) expression was
7.21-fold greater in mAo compared to D1 cells and fibroblast
growth factor 2 (Fgf2) is only expressed in mAo cells. Pdgfb
and Fgf2 both stimulate MSC proliferation and migration
of MSC, while inhibiting their adipogenic and osteogenic
differentiation [40, 41, 45]. Transforming growth factor beta
3 (Tgfb3), a growth factor that influences chondrogenic dif-
ferentiation, is expressed 3.52-fold greater in mAo compared
to D1 cells [46].
Extracellular Matrix, Cell Adhesion, and Cytoskeletal Ele-
ments. When examining expression of genes associated with
the extracellular matrix, cell adhesion, and cytoskeletal ele-
ments (Figure 4(a) and Table 1), we found melanoma cell
adhesion molecule (Mcam) expression was detectable in
mAo progenitors but not in D1 cells consistent with the
perivascular origin of the mAo [49, 50]. Matrix metallopep-
tidase 2 (Mmp2), nestin (Nes), and vascular cell adhesion
molecule 1 (Vcam1) were also expressed inmAo but not in D1
cells. Collagen, type I, alpha 1 (CoI1𝛼1), and Vimentin (Vim)
expression were 3.03- and 5.05-fold, respectively, greater in
mAo compared to D1 cells while Integrin alpha 6 (Itga6)
expression was 3.25-fold greater in D1 cultures. Expression
of Mmp2 and Vim in mAo provides a mechanism for their
migration within the perivascular region [51, 55]. Vcam1
mediates the attachment of hematopoietic cells and serves
as a marker for MSC with T-cell immunosuppressive activity
[53, 54] pointing to mechanisms through which the mAo can
interact with immune cells. In contrast, Itga6 expression is
greater in D1 and functions to enhance MSC multipotency
through specific transcription factors likeOct4 and Sox2 [48],
while nestin, which is also associated with multipotency [52],
is expressed only by the mAo cells. Therefore, mAo and D1
progenitor cells express genes which suggest they maintain
their proliferative capacity and multipotency through differ-
ent mechanisms.
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Figure 4: Mesenchymal stem cell-associated genes differentially expressed in mAo and D1 progenitor cells. (a) Clustergram demonstrating
differentially expressed genes after normalizing to Gapdh, Hprt, and Tbp as shown in Table 1. Relative expression is indicated in the order of
the target genes with the lowest expression at the top of each cluster. Red indicates greater expression, green indicates lower expression, black
indicates very low expression, and black with a white X indicates no expression (Cq ≥ 30). (b) Relative expression of the Ppar𝛾, Runx2, Sox2,
and Sox9 transcription factors in mAo and D1 progenitor cells using the Gapdh gene to normalize. Data are presented as mean ± SD, 𝑛 = 3
separate experiments. Significant differences were determined using 𝑡-test. ∗∗∗𝑃 < 0.0001.
Immune-Related/Miscellaneous. The genes that are related
to immune function (Figure 4(a), Table 1) include jagged 1
(Jag1), interleukin-6 (IL-6), leukemia inhibitory factor (Lif),
and notch gene homolog 1 (Drosophila) (Notch1). Notch1,
only present in mAo cells, is a cell surface receptor for
Jag1 which is expressed 22.11-fold greater in mAo versus
D1 cells. The Notch1/Jag1 signaling pathway is required for
MSC induction of regulatory T-cell expansion and points to
the potential for mAo progenitor interaction and regulation
of the adaptive immunity [59]. In line with this, Il-6, a
cytokine that when secreted by MSC inhibits lymphocyte
apoptosis [60] and suppresses dendritic cell differentiation
[61], is expressed only by mAo progenitors. Lif transcripts
were also only detected inmAo cells.The product of this gene
is involved in upregulation of MSC pluripotency markers
[62].
Frizzled homolog 9 (Fzd9) does not fit any category yet
described and falls under miscellaneous. Fzd9 is expressed
by D1 and not mAo cells (Figure 4(a), Table 1). This gene is
upregulated during early osteogenic differentiation [58] and
its expression by D1 cells is consistent with their osteogenic
transcription and growth factor gene-expression profile.
4. Summary
Data from the cytokine phagocytosis analyses establish that
the D1 bone marrow derived progenitors suppress the MΦ
inflammatory profile but have no effect on zymosan-induced
MΦ phagocytosis, while progenitors derived from the aorta
(mAo) contribute to MΦ inflammation activated by LPS and
support zymosan-induced MΦ activity.
The correlation of immune function and gene array
studies revealed three major themes. (1) Expression patterns
of transcription and growth factors suggest that the mAo
mesenchymal progenitors, which enhanceMΦ inflammatory
responses, are poised to differentiate into chondrocytes, while
D1mesenchymal progenitors, which suppressMΦ inflamma-
tory responses, are poised to differentiate into osteoblasts and
adipocytes. (2) mAomesenchymal progenitors express genes
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which are consistent with interaction and regulation of the
adaptive immunity. (3)The transcriptional patterns of the D1
mesenchymal progenitor and the aortic tissue derived mAo
mesenchymal progenitor suggest that they maintain their
proliferative capacity and multipotency through different
mechanisms. Itmust be noted that in addition to tissue source
these progenitor populations differ in passage number, poten-
tially contributing to the phenotypic and immunoregulatory
differences observed in these studies.
5. Conclusion
These studies demonstrate a functional heterogeneity among
mesenchymal progenitor populations derived from different
tissues in the regulation of macrophage cells. A major
finding indicates that mesenchymal progenitors expressing
surface antigens, transcription, and growth factors associated
with adipogenic and osteogenic differentiation suppress LPS-
induced macrophage inflammation.These data will be useful
for the isolation, purification, andmodification of mesenchy-
mal progenitors to be used in the treatment of inflammatory
diseases.
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mal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell
population during the differentiation process of Th1 and Th17
cells,” StemCell Research&Therapy, vol. 4, no. 3, article 65, 2013.
[8] M. H. Abumaree, M. A. Al Jumah, B. Kalionis et al., “Human
placental mesenchymal stem cells (pMSCs) play a role as
immune suppressive cells by shifting macrophage differ-
entiation from inflammatory M1 to anti-inflammatory M2
macrophages,” Stem Cell Reviews and Reports, vol. 9, no. 5, pp.
620–641, 2013.
[9] D.-I. Cho, M. R. Kim, H.-Y. Jeong et al., “Mesenchymal
stem cells reciprocally regulate the M1/M2 balance in mouse
bone marrow-derived macrophages,” Experimental & Molecu-
lar Medicine, vol. 46, no. 1, article e70, 2014.
[10] J. Maggini, G. Mirkin, I. Bognanni et al., “Mouse bone marrow-
derivedmesenchymal stromal cells turn activated macrophages
into a regulatory-like profile,” PLoS ONE, vol. 5, no. 2, Article
ID e9252, 2010.
[11] K. Anton, D. Banerjee, and J. Glod, “Macrophage-associated
mesenchymal stem cells assume an activated, migratory, pro-
inflammatory phenotype with increased IL-6 and CXCL10
secretion,” PLoS ONE, vol. 7, no. 4, Article ID e35036, 2012.
[12] J. F. Evans, V. Salvador, S. George, C. Trevino-Gutierrez, and
C. Nunez, “Mouse aorta-derived mesenchymal progenitor cells
contribute to and enhance the immune response ofmacrophage
cells under inflammatory conditions,” Stem Cell Research &
Therapy, vol. 6, no. 1, article 56, 2015.
[13] P. Anderson, A. B. Carrillo-Gálvez, A. Garćıa-Pérez, M. Cobo,
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